+2.8%
GLD vs MRNA
+945.0%
-942.2%
-28.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.7% | +13.1% | -9.4% | +3.2% |
| 7D | -0.3% | +20.6% | -20.9% | -0.9% |
| 30D | -1.9% | +27.1% | -29.0% | -2.7% |
| 3M | -0.4% | +353.4% | -353.8% | -8.5% |
| 6M | -10.2% | +446.3% | -456.4% | -19.8% |
| YTD | -6.0% | +776.2% | -782.2% | -17.3% |
| 1Y | +2.8% | +987.9% | -985.1% | -10.5% |
| All | +2.8% | +945.0% | -942.2% | -10.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling